Article Text

other Versions

PDF

Abatacept inhibits structural damage progression in rheumatoid arthritis: results from the long-term extension of the AIM trial
  1. Harry K Genant (harry.genant{at}ucsf.edu)
  1. UCSF, United States
    1. Charles G Peterfy (charles.peterfy{at}synarc.com)
    1. Synarc, United States
      1. René Westhovens (rene.westhovens{at}uz.kuleuven.ac.be)
      1. University Hospital Leuven, Belgium
        1. Jean-Claude Paul Becker (jeanclaude.becker{at}bms.com)
        1. Bristol-Myers Squibb, United States
          1. Richard Aranda (richard.aranda{at}bms.com)
          1. Bristol-Myers Squibb, United States
            1. George Vratsanos (george.vratsanos{at}bms.com)
            1. Bristol-Myers Squibb, United States
              1. Julie Teng (julie.teng{at}bms.com)
              1. Bristol-Myers Squibb, United States
                1. Joel M Kremer (jkremer{at}joint-docs.com)
                1. The Center for Rheumatology, Albany, United States

                  Abstract

                  Objective: Assess the effect of abatacept on structural damage progression over 2 years in patients with rheumatoid arthritis (RA) with an inadequate response to methotrexate (MTX).

                  Methods: 539 patients entered an open-label extension of the AIM trial and received abatacept. Radiographic assessment of the hands and feet was performed at baseline, year 1 and year 2. At year 2, each patient's radiographs were scored for progression blinded to sequence and treatment allocation.

                  Results: In patients treated with abatacept for 2 years, greater reduction in structural damage progression was observed in year 2 than in year 1. The mean change in total Genant-modified Sharp scores was reduced from 1.07 units in year 1 to 0.46 units in year 2. Similar reductions were observed in erosion and joint space narrowing scores. Following 2 years of treatment with abatacept, 50% of patients had no progression of structural damage as defined by a change in the total score of ≤0 compared with baseline. Fifty-six percent (56%) of abatacept-treated patients had no progression during the first year compared with 45% of placebo-treated patients. In their second year of treatment with abatacept, more patients had no progression than in the first year (66% vs 56%).

                  Conclusion: Abatacept has a sustained effect that inhibits structural damage progression. Furthermore, the mean change in radiographic progression in patients treated with abatacept for 2 years was significantly lower in year 2 versus year 1, suggesting that abatacept may have an increasing disease-modifying effect on structural damage over time.

                  • abatacept
                  • radiography
                  • rheumatoid arthritis
                  • structural damage

                  Statistics from Altmetric.com

                  Request permissions

                  If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.